Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Piemonte

Interventional Cardiology Burlington, MA Medical Doctor

NPI 1225134067 CMS profile 55278

Lahey Clinic, 41 Mall Rd., Burlington, MA 01805

Open in the dashboard

General payments

$330,466

93 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$497,323

7 holdings reported · through program year 2025

Through program year 2025, Thomas Piemonte of Burlington, MA is reported in the CMS Open Payments database as having received $330,466 across 93 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $497,323 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,265 8
2024 General $187,774 14
2023 General $5,397 11
2022 General $84 2
2021 General $21,540 17
2020 General $78,282 15
2019 General $33,123 26
2022 Ownership $0 1
2021 Ownership $78,948 1
2020 Ownership $178,947 2
2019 Ownership $239,427 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Piemonte
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Thomas Piemonte were reported at $4,265. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Thomas Piemonte Interventional Cardiology median Middle half National median
2019 $33,123 $1,097 $329–$3,048 $163
2020 $78,282 $473 $161–$1,480 $114
2021 $21,540 $677 $233–$1,827 $132
2022 $84 $978 $333–$2,724 $149
2023 $5,397 $1,136 $382–$2,986 $160
2024 $187,774 $1,181 $395–$3,326 $164
2025 $4,265 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $185,259 1 payment
  2. Anika Therapeutics, Inc. $85,163 4 payments
  3. Abbott Laboratories $48,600 63 payments
  4. Spirus Medical LLC $8,149 7 payments
  5. Edwards Lifesciences Corporation $1,952 15 payments
  6. Primo Medical Group, Inc. (f.k.a. STD Med Inc.) $1,125 1 payment
  7. Medtronic, Inc. $135 1 payment
  8. Chiesi USA, Inc. $84 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $201,199 2 payments
  2. Current or prospective ownership or investment interest $69,223 3 payments
  3. Consulting Fee $43,875 16 payments
  4. Royalty or License $8,010 4 payments
  5. Travel and Lodging $3,290 29 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,575 1 payment
  7. Food and Beverage $2,211 37 payments
  8. Gift $84 1 payment
Products named General payments · program years 2019–2025
  1. AMPLATZER Occluders Cardiac Arrhythmias and Heart Failure $38,210 29 payments
  2. AMPLATZER Occluders Structural Heart $3,162 5 payments
  3. AMPLATZER TALISMAN $2,708 5 payments
  4. AMPLATZER $2,640 6 payments
  5. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $999 7 payments
  6. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $677 4 payments
  7. Mitra Clip system $350 4 payments
  8. NAVITOR $150 1 payment
  9. COREVALVE EVOLUT R $135 1 payment
  10. KENGREAL $84 1 payment
  11. Other $194 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

109

Median for Interventional Cardiology: 2,236

Drug cost

$1,393

Median for Interventional Cardiology: $380,412

Branded share of claims

0%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 18 $485
Rosuvastatin Calcium Generic 15 $401
Losartan Potassium Generic 30 $293
Atorvastatin Calcium Generic 15 $118
Amlodipine Besylate Generic 31 $96

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$78,091

Medicare's payments for the services billed

Medicare patients

274

Average age 79

Services billed

512

107 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 71%
Arthritis 47%
Heart failure 43%
Atrial fibrillation 43%
Chronic kidney disease 43%
Diabetes 34%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record